2. Signaling Pathways
  3. Immunology/Inflammation
  4. NO Synthase

NO Synthase

Nitric oxide synthases; NOS

NO Synthase

Related Products

PDF 1.66 MB

Nitric oxide synthases (NOSs) are a family of enzymes catalyzing the production of nitric oxide (NO) from L-arginine. NO synthases catalyze the oxidation of L-arginine to NO and L-citrulline. Mammals contain three NOS isoforms: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). NO produced from these different NOS isoforms is involved in a wide range of physiologic functions in the nervous, immune, and cardiovascular systems. Unregulated NO production can lead to pathologic conditions such as stroke, inflammation, and hypertension. Therefore, the control of NOS activity by isoform selective NOS inhibitors has great potential for therapeutic treatments of NO-related diseases.

NO Synthase Isoform Specific Products:

NO Synthase Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-130658
    D-NMMA acetate
    		Control
    D-NMMA acetate is an inactive isomer of L-NMMA (HY-18732A). L-NMMA is a nitric oxide synthase inhibitor.
    D-NMMA acetate
  • HY-169630
    DBMB
    		Inhibitor
    DBMB is an inhibitor of spleen tyrosine kinase (Syk), capable of significantly inhibiting the activity of Syk kinase. DBMB exhibits anti-inflammatory activity by suppressing the signaling of NF-κB, which in turn reduces the production of inflammatory mediators such as nitric oxide (NO) and prostaglandin E2 (PGE2). DBMB can be utilized in research on inflammatory diseases.
    DBMB
  • HY-N4314R
    Scutellarein tetramethyl ether (Standard)
    		Inhibitor
    Scutellarein tetramethyl ether (Standard) is the analytical standard of Scutellarein tetramethyl ether. This product is intended for research and analytical applications. Scutellarein tetramethyl ether (4',5,6,7-Tetramethoxyflavone) is a bioactive compound extracted from Eupatorium odoratum. Scutellarein tetramethyl ether exhibits anti-inflammatory, antibacterial, pro-coagulant, and anti-tumor activities. Scutellarein tetramethyl ether exerts its anti-inflammatory effects by modulating the NF-κB pathway and regulates bacterial resistance through the inhibition of efflux pumps. Additionally, Scutellarein tetramethyl ether accelerates coagulation time via the endogenous coagulation pathway. Studies have shown that Scutellarein tetramethyl ether can effectively inhibit the growth of the liver cancer cell line HepG2 (IC50= 20.08 μg/mL).
    Scutellarein tetramethyl ether (Standard)
  • HY-N9814
    Shanciol B
    		Inhibitor
    Shanciol B, isolated from the ethyl acetate extract of the air-dried whole plant of Pholidota imbricate Hook, inhibits nitric oxide (NO) production and 1,1-diphenyl-2-picrylhydrazil (DPPH) radical scavenging activity. Shanciol B is a microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor with anti-inflammatory activity.
    Shanciol B
  • HY-172871
    Anti-inflammatory agent 102
    		Inhibitor
    Anti-inflammatory agent 102 (Compound 11a) is an orally active anti-inflammatory agent. Anti-inflammatory agent 102 exerts its anti-inflammatory effect by blocking the activation of the ASK1/p38 MAPKs/NF-κB signaling pathway. Anti-inflammatory agent 102 has significant anti-inflammatory activity and can inhibit the release of NO, ROS, and inflammatory factors (such as IL-6, TNF-α, IL-1β). Anti-inflammatory agent 102 can be used in the study of inflammatory diseases such as ulcerative colitis (UC).
    Anti-inflammatory agent 102
  • HY-19606
    Cytogenin
    		Inhibitor
    Cytogenin (Antibiotic MI 43-37F11) is an orally active antineoplastic antibiotic. Cytogenin regulates the inflammatory cytokine, reduces the levels of iNOS, NO and IL-6 in mouse macrophages, and exhibits antidiabetic efficacy in mice. Cytogenin inhibits growth of Ehrlich ascites tumor in mouse model.
    Cytogenin
  • HY-N15505
    Cycloneroside D
    		Inhibitor
    Cycloneroside D is a novel sesquiterpene aminoglycoside compound discovered from the deep - sea - sediment fungus Trichoderma sp. SCSIOW21. Cycloneroside D has the activity of inhibiting the production of NO. In the experiment with macrophage RAW 264.7 cells, its IC50 value for inhibiting the production of NO is 42.0 μM. Cycloneroside D can be used in the research of the anti - inflammatory field.
    Cycloneroside D
  • HY-N1263
    Scutebarbatine X
    		Inhibitor
    Scutebarbatine X (Compound 2) is a neo-clerodane diterpenoids isolated from Scutellaria barbatae (Labiatae) and has anti-inflammatory properties.
    Scutebarbatine X
  • HY-B0905AR
    Tilmicosin phosphate (Standard)
    		Inhibitor
    Tilmicosin (phosphate) (Standard) is the analytical standard of Tilmicosin (phosphate). This product is intended for research and analytical applications. Tilmicosin (LY-177370) phosphate is an orally active calcium channel antagonist and macrolide antibiotic with antimicrobial activity. Tilmicosin phosphate mainly acts on the 50S subunit of bacterial ribosomes, inhibiting protein synthesis. Tilmicosin phosphate is effective in the treatment of respiratory diseases in livestock such as cattle, sheep and pigs. In addition, Tilmicosin phosphate has immunomodulatory and anti-inflammatory effects[1][2][3][4][5][6].
    Tilmicosin phosphate (Standard)
  • HY-N15745
    Anti-Heart Failure Agent 4
    		Inhibitor
    Anti-Heart Failure Agent 4 (Compound 3) is an anti-heart failure agent with anti-inflammatory activity found in processed Cornus officinalis. Anti-Heart Failure Agent 4 inhibits NO release in LPS-induced RAW264.7 cells. Anti-Heart Failure Agent 4 alleviates myocardial ischemia-reperfusion injury, reduces myocardial infarction size, and improves myocardial histopathological changes. Anti-Heart Failure Agent 4 is promising for research of heart failure.
    Anti-Heart Failure Agent 4
  • HY-170836
    NLRP3-IN-69
    		Inhibitor
    NLRP3-IN-69 (Compound 23) inhibits the activation of NF-κB p65 and the formation of NLRP3 inflammasome. NLRP3-IN-69 inhibits LPS (HY-D1056)-induced overexpression of IL-1β, iNOS and COX-2, inhibits NO generation (IC50=5.66 μM), thereby exhibiting anti-inflammatory activity.
    NLRP3-IN-69
  • HY-159516
    Sabialimon P
    		Inhibitor
    Sabialimon P (compound 16) is a NO release inhibitor (IC50=18.12 μM) with anti-inflammatory activity. Sabialimon P significantly reduces the secretion of TNF-α, iNOS, IL-6 and NF-κB and inhibits the expression of COX-2 and NF-κB/p65 in RAW264.7 cells induced by LPS (HY-D1056).
    Sabialimon P
  • HY-147306
    ZLc-002
    		Inhibitor
    ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. ZLc-002 can be used for the research of anxiety disorder and inflammation.
    ZLc-002
  • HY-W016409R
    Ethyl 3,4-dihydroxybenzoate (Standard)
    		Activator
    Ethyl 3,4-dihydroxybenzoate (Standard) (Protocatechuic acid ethyl ester (Standard)) is the analytical standard of Ethyl 3,4-dihydroxybenzoate (HY-W016409). This product is intended for research and analytical applications. Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema.
    Ethyl 3,4-dihydroxybenzoate (Standard)
  • HY-W014049
    N'-Nitro-D-arginine
    		Inhibitor
    N'-Nitro-D-arginine, a nitric oxide synthesis inhibitor, also is a vasodilator that relaxes the smooth muscles and increases blood flow to the penis, improving erections. N'-Nitro-D-arginine also inhibits neutrophil migration by blocking receptors for tumour necrosis factor alpha (TNFα) and interleukin 8 (IL8).
    N'-Nitro-D-arginine
  • HY-N2542R
    Tubeimoside III (Standard)
    		Inhibitor
    Tubeimoside III (Standard) is the analytical standard of Tubeimoside III (HY-N2542). This product is intended for research and analytical applications. Tubeimoside III is a triterpenoid saponin. Tubeimoside III has anti-inflammatory and antitumor effects. Tubeimoside III has an LD50 of 15 mg/kg by intraperitoneal injection in ICR mice. Tubeimoside III can be used for the research of tumors and inflammatory diseases.
    Tubeimoside III (Standard)
  • HY-116832
    Retrorsine N-oxide
    Retrorsine N-oxide, an N-oxide of pyrrolizidine alkaloid, is a carcinogen. Retrorsine N-oxide-derived DNA adducts are common toxicological biomarkers of pyrrolizidine alkaloid N-oxides.
    Retrorsine N-oxide
  • HY-115750
    Nω-allyl-L-arginine
    		Inhibitor
    Nω-allyl-L-arginine is a competitive and reversible inhibitor of bovine brain nitric oxide synthase (nNOS). Nω-allyl-L-arginine can inactivate nNOS in a time-dependent manner. Nω-allyl-L-arginine also is a substrate, producing L-arginine, acrolein, and H2O.
    Nω-allyl-L-arginine
  • HY-175824
    PSD-95/nNOS PPI-IN-1
    		Inhibitor
    PSD-95/nNOS PPI-IN-1 is a inhibitor targeting the PSD-95/nNOS interaction with potential blood-brain barrier penetration. PSD-95/nNOS PPI-IN-1 binds to the PSD-95 PDZ2 domain with high affinity (Ki = 19.45 μM). PSD-95/nNOS PPI-IN-1 inhibits glutamate-induced excitotoxicity by reducing intracellular ROS levels and inhibiting apoptosis. PSD-95/nNOS PPI-IN-1 significantly reduces cerebral infarct volume in rat tMCAO models. PSD-95/nNOS PPI-IN-1 can be used for the study of acute ischemic stroke.
    PSD-95/nNOS PPI-IN-1
  • HY-18729
    L-NAME
    		Inhibitor
    L-NAME inhibits NOS with an IC50 of 70 μM. L-NAME is a precursor to NOS inhibitor L-NOARG which has an IC50 value of 1.4 μM.
    L-NAME
Cat. No. Product Name / Synonyms Application Reactivity
NO Synthase Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.